Neranol (Tapentadol)

Tapentadol provides pain relief through a dual mechanism: it activates mu‑opioid receptors, delivering classic opioid analgesia, and simultaneously blocks the reuptake of norepinephrine, which enhances descending inhibitory pathways in the spinal cord, together reducing the perception of pain.

The appropriate dose of Neranol is determined by the prescribing clinician based on the individual’s pain severity, prior opioid exposure, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for tapentadol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Neranol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional opioids such as morphine, tapentadol offers a dual mechanism that may provide effective analgesia with a potentially lower incidence of some opioid‑related side effects. However, it still carries risks of respiratory depression, dependence and other opioid‑class adverse events.

Neranol should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date indicated on the label.

Neranol is intended for oral administration. The tablet should be swallowed whole with a glass of water and may be taken with or without food, unless the prescribing information advises otherwise.

The most serious risks include respiratory depression, which can be life‑threatening, especially when combined with other depressants; the potential for severe hypotension; seizures; serotonin syndrome when used with serotonergic drugs; and the development of physical dependence or addiction.

Neranol is contraindicated in patients with known hypersensitivity to tapentadol or any component of the formulation, in those with severe respiratory depression, acute or severe bronchial asthma, or in individuals who have taken monoamine oxidase inhibitors within the past 14 days.